Royalty Pharma vs Verastem
Royalty Pharma (RPRX) and Verastem (VSTM) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $39.4B
- Last close
- $68.45
- 12 months
- +78.3%
- Market value
- $798M
- Last close
- $6.33
- 12 months
- −35.5%
At a glance
- By market value, Royalty Pharma ($39.4B) is about 49 times Verastem ($798M).
- Over the last 12 months Royalty Pharma's share price moved +78.3% and Verastem's −35.5%; against the S&P 500 that is +72.6 points and −41.2 points.
- In their last fiscal years Royalty Pharma kept 32.4% of revenue as net income and Verastem -677.6%.
- In the last 90 days insiders reported 0 open-market purchases at Royalty Pharma and 0 at Verastem; members of Congress disclosed 0 trades in Royalty Pharma and 0 in Verastem.
- Next results: Royalty Pharma Feb 9, 2027, Verastem Mar 2, 2027.
Share prices on one chart
Royalty Pharma and Verastem, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Royalty Pharma RPRXNASDAQ · Pharmaceutical Preparations | Verastem VSTMNASDAQ · Pharmaceutical Preparations | |
|---|---|---|
| Size and profitability | ||
| Market value | $39.4B | $798M |
| Revenue, last fiscal year | $2.38B | $30.9M |
| Net income, last fiscal year | $771M | −$209M |
| Net marginNet income as a share of revenue | 32.4% | -677.6% |
| Free cash flow | $2.49B | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Common questions
How is Royalty Pharma different from Verastem?
Royalty Pharma (RPRX) is in Pharmaceutical Preparations on NASDAQ, with $2.38B of revenue in its last fiscal year and a net margin of 32.4%. Verastem (VSTM) is in Pharmaceutical Preparations on NASDAQ, with $30.9M of revenue in its last fiscal year and a net margin of -677.6%. Both are in the same industry, so the gap is mostly one of size and profitability. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Royalty Pharma and Verastem compare in size?
Royalty Pharma has the larger market value: Royalty Pharma $39.4B and Verastem $798M, at the last close.
Whose share price rose more over the last 12 months, RPRX or VSTM?
Over the last 12 months Royalty Pharma moved +78.3% and Verastem −35.5%. Past price moves say nothing about the future.
Which has had more insider buying, Royalty Pharma or Verastem?
Since 2006, Verastem insiders reported 104 open-market purchases against 18 for Royalty Pharma. These are counts of what was filed, not a view on either stock.
Do members of Congress trade RPRX or VSTM?
In the last 12 months, members of Congress disclosed 0 trades in Royalty Pharma (RPRX) and 0 in Verastem (VSTM).
When did insiders last buy RPRX and VSTM?
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Royalty Pharma pageVerastem pageRare insider trades this weekAll comparisons
https://oqro.io/compare/rprx-vs-vstm

